Therapy Areas: Vaccines
RDIF states Sputnik V shows 80% efficacy against COVID in San Marino from six to eight months following second dose
25 November 2021 -

The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) disclosed on Wednesday that the Russian Sputnik V vaccine demonstrated 80% effective against coronavirus infection from six to eight months after administering the second dose.

This data is based on the number of COVID infections in the Ministry of Health of the Republic of San Marino in November 2021. Efficacy was calculated based on data obtained from over 18,600 individuals fully vaccinated with Sputnik V not less than five months before November. Over 70% of the adult population of San Marino have been vaccinated with Sputnik V.

RDIF added that the efficacy of Sputnik V on 6-8 months is much higher than officially published efficacy of mRNA vaccines. Sputnik team believes that adenoviral vaccines provide for longer efficacy than mRNA vaccines due to longer antibody and T-cell response.

According to RDIF, the hospitalization rate with COVID infection following vaccination with Sputnik V in San Marino was only 0.75 per 1,000 people during the entire mass vaccination from February to November 2021, which is two times lower than that of any other vaccine.

An article published in EClinicalMedicine revealed Sputnik V has a high safety profile in San Marino. The vaccine shows high tolerability profile in ≥60 age group with all reported adverse events following immunization being mild or moderate and lasting less than two days.